Trial Search Results

Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)

To assess whether changes in quantitative tumor perfusion parameters after 3 weeks of treatment, as measured by power doppler ultrasound, can predict initial objective response, defined by current standard-of-care, to therapy at 12 weeks after start of treatment

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: National Institutes of Health (NIH)

Stanford Investigator(s):


  • Diagnostic Test: Doppler Ultrasound
  • Device: Vantage 256 with C5-2v transducer




Inclusion Criteria:

   - 18 years of age or older

   - Pathology-confirmed diagnosis of metastatic RCC now

   - at least one tumor lesion greater than 1 cm in diameter, amenable to ultrasound

   - planned to be treated with VEGFR2 tyrosine kinase inhibitor plus immune checkpoint

   - written informed consent.

Exclusion Criteria:

-Any comorbid condition that, in the opinion of the treating provider or the Protocol
Directors, compromises the participant's ability to participate in the study.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Christian Hoerner, PhD